{
  "@context": {
    "dcterms": "http://purl.org/dc/terms/",
    "cito": "http://purl.org/spar/cito/",
    "deo": "http://purl.org/spar/deo/"
  },
  "@id": "https://hypothesis.bioagent.ai/fjcd8yik7pw",
  "@type": "deo:FutureWork",
  "cito:usesDataFrom": [
    "https://doi.org/10.1186/s13041-024-01028-8",
    "https://doi.org/10.1371/journal.pone.0172640",
    "https://doi.org/10.1002/dad2.12391",
    "https://doi.org/10.1186/s13195-022-01128-y"
  ],
  "dcterms:references": [
    "# Mechanistic Hypothesis Connecting DOPAL's Anti-Oligomerization Effect and Carbidopa's Lack of Impact on Amyloid-β Processing\n\n## 1. Background\nDOPAL (3,4-dihydroxyphenylacetaldehyde) is a reactive aldehyde produced during dopamine metabolism by monoamine oxidase (MAO), which has been shown to decrease Aβ oligomerization in human neuroblastoma cells, thereby reducing Aβ-mediated cytotoxicity. Carbidopa is a peripheral dopa decarboxylase inhibitor that prevents the conversion of levodopa to dopamine outside the central nervous system but exhibits minimal impact on Aβ generation in neuronal cells. Interestingly, L-DOPA administration has demonstrated paradoxical effects, reducing Aβ plaque burden in 5xFAD mice by upregulating clearance enzymes (Abstract 1), while other research suggests L-DOPA enhances Aβ generation through D2 receptor-mediated β-arrestin pathways in cellular models (Abstract 2).\n\n## 2. Knowledge Gap\nThe contradictory roles of dopaminergic modulation in Aβ processing remain poorly understood, particularly the mechanistic relationship between DOPAL's inhibitory effect on Aβ oligomerization and the broader dopamine metabolic pathway. Specifically, we lack understanding of how carbidopa's lack of effect on Aβ generation relates to DOPAL's anti-oligomerization properties, despite both compounds affecting different aspects of the same metabolic pathway.\n\n## 3. Central Hypothesis\nDOPAL functions as a reactive conformational modifier of nascent Aβ peptides, creating DOPAL-Aβ adducts that resist oligomerization and preferentially interact with clearance enzymes upregulated by dopamine signaling, establishing an adaptive metabolic feedback loop independent of peripheral dopa decarboxylase inhibition.\n\n## 4. Proposed Mechanism\n1. Neuronal dopamine signaling through D2 receptors activates β-arrestin pathways, enhancing γ-secretase activity and increasing Aβ production, as evidenced in Abstract 2.\n2. Simultaneously, intraneuronal dopamine undergoes MAO-mediated oxidation to produce DOPAL, which acts as a reactive electrophile capable of forming covalent adducts with specific lysine residues in newly synthesized Aβ peptides.\n3. These DOPAL-Aβ adducts adopt conformations that sterically hinder β-sheet formation necessary for oligomerization, thereby preventing the formation of toxic Aβ oligomers while maintaining the peptides in a monomeric state.\n4. The modified conformation of DOPAL-Aβ adducts increases their binding affinity and proteolytic susceptibility to clearance enzymes like neprilysin (NEP) and ADAM17, which are upregulated by dopamine signaling pathways as observed in Abstract 1.\n5. This creates a homeostatic balance where increased dopamine signaling simultaneously increases both Aβ production and the DOPAL-mediated protective pathway that prevents oligomerization and enhances clearance, explaining why L-DOPA reduces plaque burden in vivo despite increasing Aβ production in vitro.\n\n## 5. Testable Predictions\n1. Selective inhibition of monoamine oxidase B (MAO-B) in neuronal cultures and AD mouse models should decrease DOPAL production and consequently increase Aβ oligomerization and neurotoxicity, despite unaltered total Aβ production rates.\n2. Mass spectrometry analysis of brain tissue from L-DOPA-treated AD model mice should reveal the presence of specific DOPAL-Aβ adducts that are absent or reduced in untreated controls, with the abundance of these adducts correlating negatively with oligomeric Aβ levels.\n3. Neuronal cells engineered to overexpress aldehyde dehydrogenase (ALDH, which metabolizes DOPAL to DOPAC) should exhibit increased vulnerability to Aβ oligomerization and toxicity compared to control cells when exposed to equivalent concentrations of dopamine or L-DOPA.\n\n## 6. Potential Experimental Approaches\n1. Develop a multi-modal tracking system in neuroblastoma cells using fluorescently-tagged Aβ combined with DOPAL-specific fluorescent probes to visualize the real-time formation of DOPAL-Aβ adducts and their subsequent trafficking and degradation. This could be coupled with pharmacological manipulation of dopamine metabolism (using MAO inhibitors, ALDH inhibitors, and carbidopa/L-DOPA) to determine how modulating specific steps in dopamine metabolism affects DOPAL-Aβ interactions and oligomerization.\n\n2. Generate a transgenic mouse model with neuron-specific conditional knockdown of MAO-B crossed with 5xFAD mice to examine whether reducing DOPAL formation affects the progression of Aβ pathology in vivo. These mice could be treated with L-DOPA with or without carbidopa to determine if the protective effects of L-DOPA on Aβ plaque burden are dependent on central DOPAL production. Biochemical analysis of brain tissue would focus on identifying and quantifying DOPAL-Aβ adducts using mass spectrometry and correlating their presence with measures of oligomeric Aβ, plaque burden, and cognitive performance.\n\nThis hypothesis explains why carbidopa shows minimal effect on Aβ generation while accommodating the seemingly contradictory effects of L-DOPA on Aβ pathology across different experimental paradigms. It proposes a novel role for DOPAL as a physiological regulator of Aβ oligomerization through direct chemical modification, establishing a mechanistic link between dopamine metabolism and protection against Aβ-mediated neurotoxicity."
  ],
  "dcterms:subject": [
    "amyloid beta",
    "neuronal response"
  ],
  "dcterms:source": [
    "DOPAL, a dopamine metabolite, decreases Aβ oligomerization in human neuroblastoma cells, reducing the cytotoxic effects of Aβ.",
    "Carbidopa showed little to no effect on amyloid-β generation in neuronal cells when tested alongside other anti-Parkinson's medications."
  ],
  "dcterms:abstract": [
    "Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L‑DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail. Here, we investigated whether L‑DOPA treatment alters neuroinflammation, Aβ pathology, and tau phosphorylation in 5xFAD mice, a model of AD. We found that L‑DOPA administration significantly reduced microgliosis and astrogliosis in 5xFAD mice. In addition, L‑DOPA treatment significantly decreased Aβ plaque number by upregulating NEP and ADAM17 levels in 5xFAD mice. However, L‑DOPA‑treated 5xFAD mice did not exhibit changes in tau hyperphos‑phorylation or tau kinase levels. These data suggest that L‑DOPA alleviates neuroinflammatory responses and Aβ pathology but not tau pathology in this mouse model of AD.",
    "Although levodopa is the first-line medication for the treatment of Parkinson's disease (PD) showing unsurpassable efficiency, its chronic use causes dyskinesia. Accordingly, dopamine agonists are increasingly employed as monotherapy or in combination with levodopa to reduce the risk of motor complications. It is well recognized that patients with PD often exhibit cognitive deficits. However, clinical and animal studies assessing the effects of dopaminergic medications on cognition are controversial. Amyloid-β (Aβ) is one of the major hallmarks of Alzheimer's disease (AD), leading to progressive memory loss and cognitive deficit. Interestingly, the abnormal accumulation of Aβ is also detected in PD patients with cognitive deficits. Evidence indicated that levodopa induced a mild increase of Aβ plaque number and size in the brain of AD mouse. However, the underlying mechanism is unclear. Here we present that both levodopa and piribedil enhance the generation of Aβ and the activity of γ-secretase in human neuronal cells and primary neurons isolated from AD mouse. This effect was reduced by either the antagonism or the knockdown of dopamine D2 receptor (D2R). We further showed that in the cells expressing β-arrestin 2-biased D2R mutant, piribedil promoted cellular Aβ production to the extent comparable to the wild-type D2R whereas this activity was absent in those with G protein-biased D2R mutant. Moreover, the knockdown of β-arrestin 2 attenuated the increases of Aβ generation and γ-secretase activity mediated by levodopa or piribedil. Thus, our study suggests that targeting D2R-mediated β-arrestin function may have potential risk in the modulation of Aβ pathology.",
    "[18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. This study assessed 146 individuals evaluated with [18F]AZD4694 at baseline and a 2‐year follow‐up, revealing longitudinal patterns of Aβ accumulation. Results showed that cognitively unimpaired older adults displayed subtle Aβ accumulation, while Aβ positive cases exhibited greater increases, underscoring the agent’s potential to monitor Aβ levels in clinical settings.",
    "Granulovacuolar degeneration bodies (GVBs) are intracellular vesicular structures that commonly accompany pathological tau accumulations in neurons of patients with tauopathies. In this study, we show that GVBs are independently induced by tau and α-synuclein pathology, providing insights into their formation and implications in neurodegenerative diseases."
  ]
}